Acambis
Cambridge
About Acambis
Acambis plc, a biotechnology company, engages in the research, development, and manufacture of vaccines for the prevention and treatment of infectious diseases in Europe and North America. The company offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline also includes ChimeriVax-West Nile, a Phase II clinical trial candidate against West Nile virus and North America's endemic mosquitoborne encephalitis; and acam-flu-a, a Phase I clinical trial candidate against influenza vaccination and pandemic influenza. In addition, the company's products comprise ACAM-CdifF, a Phase I trial vaccine in clinical development against hospital-acquired infection; Herpes Simplex Virus against sexually transmitted infections; and ChimeriVax-Dengue, an advanced Phase II trial vaccine against the haemorrhagic fever. Acambis plc was formerly known as Peptide Therapeutics Group PLC and changed its name to Acambis plc in December, 2000. The company was founded in 1992 and is based in Cambridge, United Kingdom. As of September 25, 2008, Acambis plc operates as a subsidiary of Sanofi Pasteur SA.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Website: acambis.com
- Phone: 44 12 2327 5300
Canonical: https://fsome.com/organization/acambis-3583619 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.